Back to Search
Start Over
The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents
- Source :
- Blood; December 2016, Vol. 128 Issue: 22 p4185-4185, 1p
- Publication Year :
- 2016
-
Abstract
- Jourdan: Bayer Pharma AG: Employment. Berthold:Bayer Pharma AG: Employment. Rossi:Gilead: Honoraria, Research Funding; Abbvie: Honoraria; Janseen: Honoraria. Lange:Bayer Pharma AG: Employment. Politz:Bayer Pharma AG: Employment.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 128
- Issue :
- 22
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53052144
- Full Text :
- https://doi.org/10.1182/blood.V128.22.4185.4185